Aligos Therapeutics to Present Five Hepatitis B Studies at The Liver Meeting 2026
Event summary
- Five abstracts accepted for presentation at The Liver Meeting 2026, November 5–9, Denver.
- Focus on pevifoscorvir sodium and ALG-170675 for chronic hepatitis B (HBV) and ALG-215007 for hepatitis delta virus (HDV).
- Poster of Distinction for immune-modulatory effects of pevifoscorvir sodium in HBeAg-positive patients.
- Presentations include preclinical and clinical data on HBV and HDV treatments.
The big picture
Aligos Therapeutics is positioning itself as a leader in HBV and HDV treatments with a strong showing at The Liver Meeting 2026. The acceptance of five abstracts underscores the company's focus on clinical and preclinical validation, which is critical in a competitive landscape where chronic liver diseases remain a high unmet medical need. The presentations could influence investor confidence and strategic partnerships as Aligos progresses its pipeline toward regulatory milestones.
What we're watching
- Clinical Validation
- Whether pevifoscorvir sodium's immune-modulatory effects and HBsAg reduction data will position it as a best-in-class HBV treatment.
- Preclinical to Clinical
- The pace at which ALG-170675 and ALG-215007 advance from preclinical profiles to human trials.
- Competitive Positioning
- How Aligos differentiates its HBV and HDV pipeline against established and emerging therapies.